National Public Radio website
2) Engagement is linked to longer medication program persistence and stronger renewal In a separate January 2026 analysis focused on persistence, members in the top quartile of engagement were, on average, on a GLP-1 medication program for over twice as long (2.2x) within the first 12 months as those in the bottom quartile
The journey from a century-old problem to a modern breakthrough is a powerful story of scientific persistence
Moreover, as the market for weight loss medications continues to grow, companies should invest in clinical research to expand the approved indications for their drugs, ensuring that they can meet the demand for effective and safe obesity treatments without violating FDA regulations
However, due to frequent changes in product offerings, market conditions, and regulatory approvals, some details may become outdated or incorrect over time
212 Furthermore, the anti-inflammatory properties of GLP-1 RAs constitute another notable effect